These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 27749422)
1. FDG DOTANOC Mismatch in In Vivo Characterization and Grading of Neuroendocrine Tumor. Mukherjee A; Agarwal KK; Bal C; Kumar R Clin Nucl Med; 2016 Dec; 41(12):e511-e513. PubMed ID: 27749422 [TBL] [Abstract][Full Text] [Related]
2. Demonstration of Treatment Response to Trans-arterial Radio-embolization (TARE) on 68Ga-DOTANOC PET/CT in a Patient With Metastatic Neuroendocrine Tumor. Vadi SK; Mittal BR; Kumar R; Parihar AS; Shukla J; Kalra N Clin Nucl Med; 2018 Sep; 43(9):e312-e313. PubMed ID: 29939955 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Therapeutic Uptake of Intrathyroid Metastasis of Midgut Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE Imaging. Vija Racaru L; Sinigaglia M; Fontaine S; DʼAure D; Courbon F; Dierickx L Clin Nucl Med; 2019 Jul; 44(7):e445-e448. PubMed ID: 31021912 [TBL] [Abstract][Full Text] [Related]
6. A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT. Treglia G; Salomone E; Petrone G; Giaccari A; Rindi G; Rufini V Clin Nucl Med; 2013 Jul; 38(7):e306-8. PubMed ID: 23486330 [TBL] [Abstract][Full Text] [Related]
7. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours. Filippi L; Scopinaro F; Pelle G; Cianni R; Salvatori R; Schillaci O; Bagni O Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):432-40. PubMed ID: 26323577 [TBL] [Abstract][Full Text] [Related]
8. Gastric Mucosal Hypertrophy Masquerading as Metastasis From Neuroendocrine Tumor of the Pancreas Detected on 68Ga-DOTANOC PET/CT. Malik D; Elumalai R; Verma R; Belho ES; Seniaray N; Mahajan H Clin Nucl Med; 2020 Jan; 45(1):74-75. PubMed ID: 31693612 [TBL] [Abstract][Full Text] [Related]
9. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Abdulrezzak U; Kurt YK; Kula M; Tutus A Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719 [TBL] [Abstract][Full Text] [Related]
10. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510 [TBL] [Abstract][Full Text] [Related]
13. 68 Ga-PSMA PET/CT in Hepatic Metastasis From Pancreatic Neuroendocrine Tumor. Chen S; Lin Z; Wang C; Miao W Clin Nucl Med; 2023 Nov; 48(11):991-993. PubMed ID: 37796174 [TBL] [Abstract][Full Text] [Related]
14. Lymphoma as a second malignancy in a patient with neuroendocrine tumor: mimicking dedifferentiation on dual-tracer PET/CT with 68Ga-DOTANOC and 18F-FDG. Jain S; Sharma P; Dhull VS; Bal C; Kumar R Clin Nucl Med; 2014 Apr; 39(4):358-9. PubMed ID: 24217543 [TBL] [Abstract][Full Text] [Related]
15. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Berzaczy D; Giraudo C; Haug AR; Raderer M; Senn D; Karanikas G; Weber M; Mayerhoefer ME Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844 [TBL] [Abstract][Full Text] [Related]
16. Primary Hepatic Neuroendocrine Tumor: Pretherapy and Posttherapy FDG PET/CT Finding. Bai X; Zhang X; Wang X Clin Nucl Med; 2019 Jan; 44(1):88-90. PubMed ID: 30394931 [TBL] [Abstract][Full Text] [Related]
17. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600 [TBL] [Abstract][Full Text] [Related]
18. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1. Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985 [TBL] [Abstract][Full Text] [Related]
19. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539 [TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT in Primary Hepatic Neuroendocrine Tumors. Ma G; Li J; Xu B; Fu L Clin Nucl Med; 2018 Mar; 43(3):192-194. PubMed ID: 29293142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]